40th week of 2016 patent applcation highlights part 10 |
Patent application number | Title | Published |
20160287616 | ANTI-FATIGUE COMPOSITION - Compositions and foods which contain (1) histidine and (2) vitamin B6 and/or carnosine are useful for treating, improving, and recovering from fatigue. | 2016-10-06 |
20160287617 | MYCOTOXIN ABSORBENT AND THE USE THEREOF IN BALANCED FOOD FOR ANIMALS - One embodiment relates to a mycotoxin adsorbent highly specific for A and B trichothecenes, and especially for vomitoxin (or deoxinivalenol) and T-2 toxin; as well as a process for the preparation of the mycotoxin adsorbent. The adsorbent may be obtained by modifying the surface of an aluminum silicate using an organic functionalized-chain compound which provides it with high polarity properties. The adsorbent may be used in the preparation of balanced animal feed that avoids the toxic effects of the trichothecenes present in the feed. The combination of the adsorbent with aluminum silicates or organic aluminum silicates may be used for the preparation of balanced animal feeds that avoid the toxic effects of mycotoxins. | 2016-10-06 |
20160287618 | COMPOSITIONS FOR USE IN THE PREVENTION OR TREATMENT OF URT INFECTIONS IN INFANTS OR YOUNG CHILDREN AT RISK - The present invention relates to a composition comprising at least one fucosylated oligosaccharide, for use in preventing and/or treating URT infections in an infant or young child fulfilling at least one of the following criteria: i) the infant or young child is born from a non-secretor mother and/or is fed with a mother's milk deficient in at least one fucosylated oligosaccharide(s) ii) the infant or young child has at least one sibling iii) the infant or young child was born by C-section. | 2016-10-06 |
20160287619 | Synthetic composition for preventing or treating CVD - The invention relates to HMOs and compositions comprising thereof for reducing the risk of, preventing, or treating CVD and/or CDV associated pathological conditions or diseases in humans, particularly in overweight and obese humans. | 2016-10-06 |
20160287620 | GLYCOCLUSTERS AND THEIR PHARMACEUTICAL USE AS ANTIBACTERIALS - A molecule responding to formula (I)of the glycocluster type with galactose residues at their extremities. Simple and efficient methods for the preparation of these compounds. Medical use of compounds (I) as inhibitors of infections by | 2016-10-06 |
20160287621 | BIOLOGICAL PRODUCTION OF NAD PRECURSORS AND ANALOGS - Aspects of the invention relate to methods for producing NAD precursors such as nicotinamide mononucleotide (NMN), comprising providing an isolated cell that overexpresses a nicotinamide phosphoribosyltransferase (Nampt) enzyme and culturing the cell in the presence of nicotinamide (NAM). | 2016-10-06 |
20160287622 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL DISORDERS AND MODULATING PROTEIN-RNA INTERACTION - The present invention relates to methods of treating or decreasing the likelihood of developing a disorder associated with immune misregulation, such as, an autoimmune disorder, or viral or virus-associated disorder in a subject including administering to the subject a composition comprising an activator of a CCCH zinc finger-containing PARP, such as, PARP13 or PARP12. The present invention also relates to methods of treating a TRAIL-resistant disorder, such as, TRAIL-resistant cancer including administering to the subject a composition comprising an activator of a CCCH zinc finger-containing PARP, such as, PARP13 or PARP12. The present invention further relates to methods of modulating a CCCH zinc finger-containing PARP-RNA interaction including contacting a CCCH zinc finger-containing PARP protein or a CCCH zinc finger-containing PARP fusion protein with a CCCH zinc finger-containing PARP activator. | 2016-10-06 |
20160287623 | USE OF STING AGONIST AS CANCER TREATMENT - Methods and compositions for treating cancer by intratumorally administering a stimulator of interferon genes (STING) agonist are disclosed herein. In some embodiments, there are provided compositions and methods concerning methods for treating cancer in a subject comprising administering to the subject an effective amount of a stimulator of interferon genes (STING) agonist, wherein the STING agonist is administered intratumorally. | 2016-10-06 |
20160287624 | Water-Soluble Vitamins to Increase Oral Absorption and Bioavailability - The present invention provides formulations for enhancing bioavailability of water-soluble compounds including water-soluble vitamins. The formulations include a water-soluble vitamin and a glycoside selected from a diterpene glycoside and a triterpene glycoside. Methods for increasing the bioavailability of a water-soluble vitamin are also described | 2016-10-06 |
20160287625 | METHODS AND MATERIALS FOR TREATING HEMATOLOGICAL MALIGNANCIES - This document provides methods and materials involved in treating hematological malignancies. For example, methods and materials for using telomerase inhibitors to treat hematological malignancies such as hematological malignancies with a spliceosome mutation genotype or presenting with ringed sideroblasts within bone marrow are provided. | 2016-10-06 |
20160287626 | METHODS OF TREATING AND PREVENTING RADIATION DAMAGE - The invention relates to methods of treating and preventing radiation damage from whole-body exposure. According to the methods of the invention, subjects are treated therapeutically and/or prophylactically with low-anticoagulant heparinoids. The invention also relates to methods of extending the life of subjects exposed to whole-body radiation. | 2016-10-06 |
20160287627 | METHOD FOR SUPPRESSING ONSET OF GASTRIC ULCER AS ADVERSE EFFECT OF DRUG, ORAL PHARMACEUTICAL COMPOSITION FOR SUPPRESSING ONSET OF GASTRIC ULCER AND METHOD FOR PRODUCING THE SAME - [Problem] To suppress the onset of adverse effects of drugs that cause gastric ulcers as an adverse effect. | 2016-10-06 |
20160287628 | METHOD OF PRODUCING PHYSIOLOGICAL AND THERAPEUTIC LEVELS OF NITRIC OXIDE THROUGH AN ORAL DELIVERY SYSTEM - A composition and method of providing nitric oxide and nitrite therapy to patients whereby a therapeutic amount is bioavailable within approximately 30 minutes of administration. In embodiments of the invention, nitric oxide is produced in the oral cavity. | 2016-10-06 |
20160287629 | MAGNESIUM-CONTAINING PRODUCTS AND USES THEREOF - A composition including a hydrate form of magnesium oxide, denoted as MgO.(H | 2016-10-06 |
20160287630 | COMPOSITIONS AND METHODS FOR COMBATING BACTERIAL INFECTIONS BY KILLING PERSISTER CELLS WITH MITOMYCIN C AND/OR CISPLATIN - The present disclosure provides a method for killing persister cells with mitomycin C and/or cisplatin, or derivatives thereof. Recalcitrant infections are difficult to treat due to persister cells, a subpopulation of all bacterial populations that is highly tolerant against all traditional antibiotics since the cells are dormant and antibiotics are designed to kill growing cells. Here, we show that MMC and cisplatin eradicate persister cells through a growth-independent mechanism, cross-linking DNA. We find both agents are effective against both planktonic cultures and highly robust biofilm cultures for a broad range of bacterial species, including commensal | 2016-10-06 |
20160287631 | NANOPARTICLE COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING TISSUE INFECTIONS AND DISEASES - Stabilized multi-component antimicrobial compositions for treating tissue diseases, infections or conditions include a first and second set of differently sized and/or differently shaped metal nanoparticles, and a stabilizing agent. Compositions and treatment methods may be used for treating tissue diseases, infections or conditions caused by microbial infections, such as bacteria, viral, and/or fungal infections, or for preventing the infection of a wound, such as a cut, abrasion, ulcer, lesion, sore, and the like. The compositions and treatment methods disclosed herein may also be used as a prophylactic, and in some embodiments may be applied to otherwise healthy tissue in order to prevent or reduce the occurrence of a tissue disease, infection or condition. | 2016-10-06 |
20160287632 | PREVENTION OF INFARCT EXPANSION - Provided are methods and kits for safe and effective therapy that can be administered early after a heart attack in order to prevent progressive heart dilatation and resultant loss of function. The therapy includes the administration of particulate compositions to a region comprising an infarct or a portion thereof. | 2016-10-06 |
20160287633 | SOLID COMPOSTITIONS BASED ON MINERALS AND ORALLY DISINTEGRATING FORMULATIONS CONTAINING THE SAME - The present invention relates to solid compositions, preferably in powder or granule form, based on minerals (semi-finished or raw material) and a process for preparing said solid compositions. Furthermore, the present invention relates to solid formulations (final products) and orally disintegrating formulations (final products) containing said solid compositions. Moreover, the present invention relates to a process for preparing said solid formulations and said orally disintegrating formulations. Finally, the present invention relates to the use of said solid compositions or said solid or orally disintegrating formulations in the treatment of disorders or diseases related to or derived from a deficiency of minerals such as magnesium (II), calcium (II), iron (III), zinc (II) and/or iodine. All the compositions or formulations of the present invention are suitable for pediatric subjects, adolescents, athletes, men, women, pregnant women and elderly. | 2016-10-06 |
20160287634 | METHOD OF MANUFACTURING AN AFOD INTRAVENOUS INJECTION FROM FRACTION IV TO PREVENT AND KILL HIV-1 AND HIV-2 - The present subject matter relates to a method of manufacturing an AFOD intravenous injection, comprising dissolving a Fraction IV1+IV4 paste with WFI; adding sodium acetate, adjusting pH and agitating until fully dissolved; cooling; performing press filtration; collecting an AFOD paste comprising newly-found proteins KH 24, KH 25, KH 26, and KH 27; dissolving the paste with a buffer; centrifuging; filtrating with a depth filter; adding Tween-80; cooling; adjusting pH and adding a cold alcohol while cooling; centrifuging to obtain a second AFOD paste; dissolving the second paste with a buffer and adjusting pH; filtrating with a depth filter; ultra-filtrating; undergoing dialysis with WFI; nano filtrating for virus removal; concentrating and adjusting pH; adding a stabilizer; and filling and performing sterile filtration to obtain the AFOD intravenous injection. The present subject matter relates to an AFOD intravenous injection in liquid or lyophilized form to prevent and kill HIV-1 and HIV-2. | 2016-10-06 |
20160287635 | TUMOR SUPPRESSION USING HUMAN PLACENTAL PERFUSATE AND HUMAN PLACENTA-DERIVED INTERMEDIATE NATURAL KILLER CELLS - Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. | 2016-10-06 |
20160287636 | COMPOSITIONS AND METHODS FOR TREATING A PATHOGENIC METABOLIC CONDITION OF THE GUT MICROBIOTA AND DERIVED DISEASES - The invention relates to the use as a drug or medical nutritional product in humans to treat a pathological dysbiosis and/or to prevent or treat at least one derived metabolic disease chosen from among excess weight with comorbidity, obesity, diabetes, heart and vascular diseases, atherosclerosis, degenerative bone disease, neurodegenerative disease, metabolism-related cancers, autoimmune diseases, steatosis, metabolic steatohepatitis, and chronic inflammatory diseases of the intestine, by increasing the | 2016-10-06 |
20160287637 | Synthetic composition and method for modulating emotion and mood disorders - The invention relates to a method for treating or preventing the development of emotion and/or mood disorders in a human individual. | 2016-10-06 |
20160287638 | ISCHEMIC TOLERANT CELLS AND CELLULAR FACTORS IN THE TREATMENT OF PERIPHERAL ARTERY DISEASE - A method for treatment of peripheral arterial disease conditions comprising systemically administering an effective amount of therapeutic stem cells. Included within the scope of the invention is intravenous administration of a therapeutic amount of ischemic tolerant mesenchymal stem cells in the treatment of peripheral arterial disease. | 2016-10-06 |
20160287639 | CO-ENCAPSULATION OF LIVE CELLS WITH OXYGEN-GENERATING PARTICLES - Microcapsules are described that comprise (a) a liquid aqueous or hydrogel core; (b) a semipermeable membrane surrounding said core; (c) live animal cells (e.g., pancreatic cells) in the core; and (d) oxygen-generating particles in said core, said oxygen-generating particles included in said microcapsules in an amount sufficient to lengthen the duration of viability of said animal cells in said microcapsules. Compositions comprising such microcapsules and uses thereof, such as in treating diabetes, are also described. | 2016-10-06 |
20160287640 | DENUDED AMNION FLOWABLE TISSUE GRAFT AND METHOD OF FORMING SAME - The invention relates to preparations and methods of creating preparations of reconstituted amniotic membrane denuded of the amniocyte/epithelial cell layer to preserve amniocytes viability during processing. The tissue graft utilizes amniotic fluid as a source of additional viable stem cells. The amniotic tissue graft is flowable and injectable, and designed for use in surgical and minimally invasive medical therapy of injury and disease to promote tissue regeneration and healing. The tissue grafts optimize available quantities of viable mesenchymal stem cells and non-cellular bioactive compounds to enhance therapeutic efficacy. The tissue grafts are semi-viscous fluids which may be intraoperatively transplanted at the recipient site using a needless syringe or by non-operative percutaneous injection through a hypodermic needle. | 2016-10-06 |
20160287641 | METHODS OF TREATING JOINT DISEASES, DISORDERS, AND CONDITIONS WITH TISSUE INHIBITORS OF MATRIX METALLOPROTEINASES - Methods for treating joint diseases, disorders, and conditions, such as osteoarthritis, with a composition containing a therapeutically effective amount of tissue inhibitors of matrix metalloproteinases (TIMPs) are provided. The composition can contain TIMPs as part of amniotic fluid, or the TIMPs can be isolated from another source or recombinantly produced. The methods are particularly useful for treating osteoarthritis associated with degradation of articular cartilage by proteases. Also provided are methods of lubricating a joint, such as an osteoarthritic joint. | 2016-10-06 |
20160287642 | METHODS OF TREATING OR PREVENTING A LUNG DISORDER - Disclosed herein are methods for preventing or treating a lung disorder using, in part, mesenchymal stem cells derived from umbilical cord tissue. The methods and uses described herein relate to the administration of or use of mesenchymal stem cells, specifically those isolated and/or enriched from umbilical cord tissue, to a subject in need thereof having a lung disorder. | 2016-10-06 |
20160287643 | TISSUE REPAIR MATERIAL DERIVED FROM FISH SKIN AND MANUFACTURING METHOD THEREOF - A tissue repair material derived from fish skin and manufacturing method thereof is applied to provide the tissue repair material suitable for use as a patch, a cover, a carrier, a scaffold, an implant or a reagent in various tissues. The tissue repair material has collagens to improve the wounded tissue repair, and has particular characters for desired tissue repair application. Furthermore, so far the factors of the terrestrial animal transmitted disease (caused by virus) do not survive on the tissue repair material derived from fish skin. | 2016-10-06 |
20160287644 | FORMULATIONS FOR BENEFICIALLY ALTERING THE MICROBIOME - Several embodiments of the invention provide a unique system of formulations adapted to beneficially alter the microbiome. In one embodiment, the invention comprises four oral formulations designed to work synergistically to assist in weight management. The formulations include three or four of the following: a cleansing formulation, a prebiotic formulation a probiotic formulation and a nutritional formulation. The formulations can be designed to work together to fundamentally change the flora of the gastrointestinal tract to achieve significant benefits. | 2016-10-06 |
20160287645 | COMPOSITION COMPRISING LACTOBACILLUS PLANTARUM - The present invention relates to strain of | 2016-10-06 |
20160287646 | MACROALGAE COMPOSITIONS, PROCESSES FOR PREPARATION THEREOF, AND USES IN SPORTS NUTRITION - Macroalgae compositions, processes for the preparation thereof, and applications thereof as a sports nutrition supplement are described. More particularly, a macroalgae composition includes a macroalgae extract including medium chain and long chain fatty acids in a ratio of about 1:0.0005 to 1:0.1. The composition is prepared by extracting macroalgae selected from green, red and/or brown algae or the combinationsusing suitable non-polar, semi-polar and polar organic and/or inorganic solvents and the combinations thereof. The composition is useful as a sports nutrition supplement in an effective daily dose, and enhances exercise endurance, resistance to muscle fatigue and/or supports protein synthesis performance. The composition is safe for human consumption and is useful as sports nutrition and for body building applications. | 2016-10-06 |
20160287648 | EXTRACT OF ALGAE FOR USE AS AN IMMUNOMODULATOR AGENT - The present invention relates to an extract of algae from the order of ulvales, in particular an extract of green algae of the | 2016-10-06 |
20160287649 | PHARMACEUTICAL COMPOSITION FOR REDUCING BODY FAT - The present invention relates to a pharmaceutical composition comprising, as active substance, | 2016-10-06 |
20160287650 | A Feed Supplement and a Feed Composition Comprising Resin Acid Based Composition - The present invention relates to a feed supplement which comprises a resin acid based composition comprising over 10% (w/w) resin acids for use in the prevention of growth of harmful bacteria in the animal digestive tract, in the prevention of intestinal disorders, in the modulation of microbial population of the animal digestive tract, in enhancing rumen fermentation, lowering rumen methane production and/or in binding toxins. The invention further relates to a use of the feed supplement and a feed composition comprising the feed supplement. | 2016-10-06 |
20160287651 | SOLID PREPARATIONS CONTAINING PELARGONIUM SIDOIDES EXTRACTS AND SILICIC ACID COMPOUND, AND PREPARING METHOD THEREOF - The present invention relates to a solid preparation including a | 2016-10-06 |
20160287652 | CANNABIS EXTRACTION METHOD AND COMPOSITIONS - The present invention provides methods of extracting | 2016-10-06 |
20160287653 | Process For The Production Of An Enriched Natural Antioxidant Mixture From A Single Source Plant - A process for extracting antioxidants from a plant, including contacting a plant material from a guayusa plant for a first time with a solvent, thereby obtaining a first slurry, filtering said first slurry, thereby obtaining a first extract, contacting said plant material for a second time with said solvent, thereby obtaining a second slurry, filtering said second slurry, thereby obtaining a second extract, combining said first extract and said second extract, thereby generating an third extract containing at least antioxidants, xanthines, and amino acids, and substantially drying said third extract. | 2016-10-06 |
20160287654 | THERAPEUTIC USES OF MASTIC GUM FRACTIONS - The invention relates to therapeutic uses of gum mastic, and compounds found therein including polymeric myrcene. More particularly, the invention relates to methods of treating impaired neurological function using compositions comprising polymeric myrcene. | 2016-10-06 |
20160287655 | EFFECTS OF A DECAFFEINATED GREEN COFFEE EXTRACT ON BODY WEIGHT CONTROL BY REGULATION OF GLUCOSE METABOLISM - A method of controlling body weight in humans by administering an amount of decaffeinated green coffee extract effective to treat a subject. A preferred green coffee extract contains a ratio of 4-caffeoylquinic acid (4-CQA) to total chlorogenic acids (tCGA) (5-CQA/tCGA) of from about 0.1 to about 0.2. More preferably, the green coffee extract comprises from about 6% to about 8% of 4-caffeoylquinic acid and has a total chlorogenic acid concentration that exceeds about 45%. A preferred method of administration consists of administering the green coffee extracts is a dosage of about 200 mg twice a day prior to meals on an empty stomach. | 2016-10-06 |
20160287656 | Herbaceutical Formulations - Described are herbaceutical effervescent formulations comprising extracts of | 2016-10-06 |
20160287657 | DIETARY SUPPLEMENT FOR THE TREATMENT OF ACID REFLUX AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD/GERD) - Use of dietary fibre material extracted from sugar cane in the manufacture of a food product that is formulated to ameliorate the effects of acid reflux and extended symptoms of gastro-oesophageal reflux disease. The product ameliorates both the acute and long term symptoms of both conditions. | 2016-10-06 |
20160287658 | COMPOSITION FOR MOISTURIZING SKIN - In an aspect, the present disclosure provides a composition for moisturizing skin, which contains a bamboo sap and a betaine as active ingredients. Specifically, the composition exhibits skin moisturizing effect by regulating natural moisturizing factors (NMFs) and is useful as a cosmetic composition, a pharmaceutical composition or a health food composition effective in moisturizing skin. | 2016-10-06 |
20160287659 | BIOGEL - A biogel, and kits, agents, and methods for formation of the biogel are described. The biogel can be used for a variety of applications, including haemostasis, wound sealing, tissue engineering or localised drug delivery. | 2016-10-06 |
20160287660 | TREATMENT OF PRIMARY AND METASTATIC CARCINOMA - Disclosed are methods of treating a chemotherapy-resistant cancer, of treating a cholangiocarcinoma, of treating a metastatic carcinoma, and of treating a transition cell urothelial carcinoma by administering a therapeutically effective amount of an endothelin B (ET | 2016-10-06 |
20160287661 | METHOD FOR TREATING CANCER BY ADMINISTERING ATP AND POLYMYXIN B - A method for treating cancer. The method including administering to a subject in need thereof, a combination including an effective amount of polymyxin B in combination with an effective amount of ATP, wherein the combination is effective in treating a tumor or cancer in the subject. | 2016-10-06 |
20160287662 | TREATMENT AND DIAGNOSIS OF OCULAR DISEASE - This invention concerns compositions and methods of treating or diagnosing ocular disease. | 2016-10-06 |
20160287663 | COMPOSITIONS AND METHODS FOR WOUND HEALING AND TISSUE REPAIR - Provided are peptides that can inhibit collagen synthesis, processing and/or secretion from scar forming cells or fibroblasts. Also provided are methods for using the peptides to produce an anti-fibrotic, anti-scarring, anti-inflammatory, and/or pro-regenerative effect, e.g., on an injured or diseased tissue. | 2016-10-06 |
20160287664 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION - In some aspects, the invention teaches pharmaceutical compositions that include a TGF-beta ligand trap, and methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-beta ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-beta signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-beta ligand trap to reduce right ventricular systolic pressure in a subject. | 2016-10-06 |
20160287665 | DENDRITIC CELL MODULATORY MOLECULE - The present invention provides a dendritic cell modulatory molecule which modulates, and preferable inhibits, the differentiation and maturation of mammalian dendritic cells. The invention also provides pharmaceutical compositions comprising the dendritic cell modulatory molecule and homologues and active fragments thereof, antibodies thereto and methods of treatment and screening methods which utilise such molecules. | 2016-10-06 |
20160287666 | PROTOXIN-II VARIANTS AND METHODS OF USE - The present invention relates to Protoxin-II variants, polynucleotides encoding them, and methods of making and using the foregoing. | 2016-10-06 |
20160287667 | METHODS AND COMPOSITIONS FOR REJUVENATING NEUROMUSCULAR JUNCTIONS - The disclosure relates to methods and compositions for rejuvenating neuromuscular junctions, and treating, preventing, or delaying the onset of, neuromuscular junction fragmentation and related disorders, neuromuscular junction degeneration and related disorders, motor neuron degeneration and related disorders, skeletal muscle conditions (e.g., muscle atrophy), and neuromuscular diseases (e.g., amyotrophic lateral sclerosis). | 2016-10-06 |
20160287668 | SANDWICHED BIODEGRADABLE MICRONEEDLE - A microneedle device for delivering therapeutic ingredients to the dermis or epidermis. The device contains biodegradable microneedles, which extend from a backing, and are sandwiched between a cap film and a film which is coextensive with the tips of the microneedles and the spaces on the backing between the microneedles. | 2016-10-06 |
20160287669 | Agent and Method for Treating Autoimmune Disease - Provided is an agent for the treatment of an autoimmune disease, the agent comprising CTRP3, and a method for the treatment of an autoimmune disease, the method comprising: administering an agent, which comprises CTRP3 for the treatment of an autoimmune disease, to a subject in need of a treatment of an autoimmune disease. | 2016-10-06 |
20160287670 | METHODS OF USE FOR IL-22 IN THE TREATMENT OF GASTROINTESTINAL GRAFT VS. HOST DISEASE - The present invention provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stem Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. In particularly preferred embodiments, the present invention provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions. | 2016-10-06 |
20160287671 | BOOSTING TREG CELLS FOR TREATING ALZHEIMER DISEASE AND RELATED DISORDERS - The present invention relates to the boosting of Treg cells for the treatment of Alzheimer's disease and related disorders. | 2016-10-06 |
20160287672 | METHOD OF TREATING CHRONIC HEART FAILURE BY ADMINISTERING RELAXIN - The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin. | 2016-10-06 |
20160287673 | COMPOSITIONS AND METHODS FOR TREATING CORNEAL EPITHELIAL WOUND - A composition comprising a peptide agent comprising amino acid sequence LKKTET (SEQ. ID NO.: 1) or Thymosin β4 (Tβ4) can treat a corneal epithelial wound caused by epithelial debridement. | 2016-10-06 |
20160287674 | Treatment Type 2 Diabetes Mellitus Patients - A pharmaceutical combination for use in glycemic control in a type 2 diabetes mellitus patient, said combination comprising (i) lixisenatide or/and a pharmaceutically acceptable salt thereof, (ii) insulin glargine or/and a pharmaceutically acceptable salt thereof, and (iii) optionally metformin or/and a pharmaceutically acceptable salt thereof. | 2016-10-06 |
20160287675 | TREATMENT FOR CANCER - The present invention provides a method of treatment for cancer in a subject comprising the administration of a prodrug, wherein the subject is colonised with an obligate anaerobic microorganism capable of expressing a polypeptide having nitroreductase activity, wherein the polypeptide exhibits preferential reduction of CB1954 to a 4-hydroxylamine (4HX) derivative instead of a 2-hydroxylamine derivative; and is capable of reducing CB1954 to the 4HX derivative with a K | 2016-10-06 |
20160287676 | TREATING GLAUCOMA, CARDIOVASCULAR DISEASES, AND RENAL DISEASES - This document provides methods and materials related to treating glaucoma, ocular hypertension, cardiovascular diseases, and renal diseases. For example, this document provides isolated nucleic acid molecules and viral vectors (e.g., lentiviral vectors) containing isolated nucleic acid molecules. Methods for reducing intraocular pressure as well as symptoms and progression of cardiovascular and renal diseases also are provided. | 2016-10-06 |
20160287677 | BACTERIAL ANTI-PHAGE DEFENSE SYSTEMS - An isolated polypeptide is disclosed comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 2773-5544 and 11089-11094, wherein the polypeptide has antimicrobial activity. Uses thereof for treating microbial infections are also disclosed. | 2016-10-06 |
20160287678 | GENE DELIVERY METHODS AND COMPOSITIONS - The invention provides methods and compositions that remove target genetic material from a subject by hydrodynamic delivery of an enzyme that degrades the target genetic material. The methods include delivering a solution include a nucleic acid, protein, or ribonucleoprotein to a blood vessel at a pressure sufficient to cause the material to enter cells proximal to the blood vessel. The enzyme may be Cas9 and may be provided with a guide RNA. The target genetic material may be viral genome with the guide RNA complementary to a portion of the viral genome. | 2016-10-06 |
20160287679 | PHARMACEUTICAL PREPARATION - The pharmaceutical preparation for the treatment of pancreatic insufficiency comprises a liquid administering form of enzymes. | 2016-10-06 |
20160287680 | ENZYMES AND METHODS FOR CLEAVING N-GLYCANS FROM GLYCOPROTEINS - Provided herein are deglycosylating enzymes that remove a broad range of N-glycans from N-glycosylated proteins. Further provided are methods of recombinantly producing and expressing the deglycosylating enzymes. The presently described deglycosylating enzymes can be used to produce free glycans for characterization, and for prebiotic and immunostimulatory uses. In addition, the presently described deglycosylating enzymes can be used to produce deglycosylated proteins for characterization, to improve digestion, and to reduce immunogenicity. | 2016-10-06 |
20160287681 | METHOD OF MANUFACTURING AND PURIFYING PROTHROMBIN COMPLEX CONCENTRATE FROM FRACTION III FOR INTRAVENEOUS INJECTION AND A METHOD OF CURING AND PREVENTING HEMOPHILIA A WITH INHIBITORS OR HEMPOPHILIA B PATIENTS INFECTED WITH HIV-1 AND HIV-2 - The present subject matter is directed to a method of manufacturing and purifying an intraveneous injection of prothrombin complex concentration (PCC) from plasma Fraction III, comprising reconstituting a Fraction III paste in a buffer to create a Fraction III suspension; adjusting pH and temperature of the Fraction III suspension; performing PEG precipitation; centrifuging the Fraction III suspension and collecting a supernatant; filtering the supernatant; performing solvent detergent virus inactivation of the supernatant; undergoing weak anion exchange chromatography of the supernatant; twice washing and eluting two to three times; ultra-filtering the supernatant; adjusting pH of the supernatant; adjusting activity of a human factor IX of the supernatant; performing aseptic filtration and nano filtration for virus removal; and filling and lyophilizing to obtain the intraveneous injection of PCC. | 2016-10-06 |
20160287682 | MODULATION OF MUSCLE AND ADIPOCYTE DISTRIBUTION AND FATE - Modulation of the ADAMTS1 signaling pathway alters the commitment of progenitor cells to a muscle fate; and increases muscle mass. | 2016-10-06 |
20160287683 | Novel Pharmaceutical Preparation for Preeclampsia, Eclampsia, and Toxemia and Their Related Symptoms and Related Disorders of Pregnancy - A therapeutic agent for the treatment of toxemia, preeclampsia and eclampsia and a method for preparing the therapeutic agent are disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or by other methods. Further, a method of using the presence of chymotrypsin in the maternal GI tract as a biomarker, to determine the likelihood of developing preeclampsia, a pregnancy induced hypertension, and eclampsia/toxemia is disclosed. | 2016-10-06 |
20160287684 | THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR BEE COLONY COLLAPSE SYNDROME - The present invention provides therapies, vaccines, and predictive methods for Colony Collapse Disorder in bees and provides compounds for diagnosing, preventing, and treating Colony Collapse Disorder, A first non-limiting aspect of the present invention provides an isolated or synthesized peptide of up to 100 amino acid residues comprising at least one peptide sequence that is at least 70%, 80%, 90%, or 95% homologous with at least one Replikin peptide sequence identified in a CCD factor in honeybees or in any honeybee including but not limited to at least one Replikin sequence identified in at least one isolate of | 2016-10-06 |
20160287685 | METHOD FOR RESTORING IMMUNE TOLERANCE IN VIVO - The present invention provides a method for restoring immune tolerance in vivo. The invention relates to the use of a recombinant gene encoding auto-antigens or parts thereof for restoring immune tolerance to the auto-antigens in vivo, under transcriptional control of polyomaviral early and late promoters. In a preferred embodiment, the invention relates to the use of recombinant polyomaviral gene delivery vector particles, such as simian virus 40 (SV40) viral vector particles encoding one or multiple auto-antigens or parts thereof under transcriptional control of the SV40 early and late promoter, for restoring immune tolerance to the auto-antigens in vivo. The invention also relates to compositions comprising recombinant genes or polyomaviral vectors and uses thereof as treatment for degenerative or dystrophic diseases. | 2016-10-06 |
20160287686 | MYELOID DERIVED SUPPRESSOR CELL INHIBITING AGENTS - Myeloid derived suppressor cell (MDSC) inhibitory agents and vaccine and/or adjuvant enhancers are provided. Improved vaccine treatment regimens employing these agents are also provided. Cancer vaccines and methods for inhibiting tumor growth and cancer metastases are also presented. The myeloid derived suppressor cell (MDSC) inhibiting agents are described as bisphosphonates (such as liposomal clodronate) and CCR2 inhibitors and/or CCR2 antagonists. Methods for enhancing antibody titer levels in response to an antigen of interest are also provided. | 2016-10-06 |
20160287687 | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against Renal Cell Carcinoma (RCC) and other cancers - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2016-10-06 |
20160287688 | INFECTIOUS PLASMODIUM SPOROZOITES GROWN IN VITRO - The application is directed to in vitro-reared | 2016-10-06 |
20160287689 | IMMUNIZATION AGAINST CLOSTRIDIUM DIFFICILE DISEASE - The invention provides active and passive immunization methods for preventing and treating | 2016-10-06 |
20160287690 | Vaccine to Protect a Ruminant Against Pneumonia Caused by Mannheimia Haemolytica - The present invention pertains to a vaccine for administration to the upper respiratory tract of a ruminant to protect said ruminant against pneumonia caused by | 2016-10-06 |
20160287691 | PRRSV COMPOSITIONS - This invention provides kits, devices, and methods for the detection of antibodies that recognize one or more proteins and/or antigens from porcine reproductive and respiratory syndrome virus (PRRSV). The antibodies may be in a biological fluid of a PRRSV infected or at risk subject. The invention may be advantageously applied to both the diagnosis and prevention of PRRSV infection. | 2016-10-06 |
20160287692 | SWINE INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 2016-10-06 |
20160287693 | REMOVAL OF RESIDUAL CELL CULTURE IMPURITIES - The present application discloses methods for removing residual impurities from protein preparations. Such methods include addition of an anionic detergent to a solution comprising proteins of interest and cellular contaminants under non-precipitating conditions and passing the solution through an ion exchange column. | 2016-10-06 |
20160287694 | PISCINE REOVIRUS IMMUNOGENIC COMPOSITIONS - The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus polypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an animal. | 2016-10-06 |
20160287695 | COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT - The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof. | 2016-10-06 |
20160287696 | PAN POLLEN IMMUNOGENS AND METHODS AND USES FOR IMMUNE RESPONSE MODULATION - The invention relates to pan pollen immunogens such as polypeptides, proteins and peptides, and methods and uses of such immunogens for modulating or relieving an immune response in a subject. For example, the immunogens can be used for treating a subject for an allergic immune response or inducing or promoting immunological tolerance to the immunogen or a pollen allergen in a subject. | 2016-10-06 |
20160287697 | INJECTABLE VACCINE COMPOSITION - The present invention aims at providing an injectable vaccine composition that is safe, useful as a prophylactic or therapeutic agent for cancers or infectious diseases, and capable of inducing the systemic immune response safely and effectively. The present invention is an injectable vaccine composition to be administered by injection to a human being or an animal, containing: at least one antigen, and as an adjuvant, a lipopolysaccharide derived from at least one gram negative bacterium selected from the group consisting of | 2016-10-06 |
20160287698 | USE OF FLUORINATED CYCLIC DINUCLEOTIDES AS ORAL VACCINE ADJUVANTS - Disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof as an adjuvant for the preparation of an oral vaccine. Further disclosed is the use of fluorinated cyclic dinucleotides and pharmaceutically acceptable salts thereof for enhancing the immune response to an orally administered vaccine. | 2016-10-06 |
20160287699 | FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER - Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient. | 2016-10-06 |
20160287700 | METHODS, APPARATUSES, AND COMPOSITIONS TO PREVENT INFECTIONS - Embodiments of the present technology may include a composition for reducing microorganisms in the anterior nares or at other body sites. The composition may include a photosensitizer and a substance that enhances the eliminating, destroying, killing, or inhibiting of microorganisms in the anterior nares. | 2016-10-06 |
20160287701 | PULSE PHOTODYNAMIC TREATMENT OF PHOTODAMAGED SKIN - A pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin is described. | 2016-10-06 |
20160287702 | Method of Improving Immune Function in Mammals using Lactobacillus Strains with Certain Lipids - A method of improving immune-function in mammals using selected 3-HPA producing lactic acid bacteria with a medium chain triglyceride (MCT) oil. | 2016-10-06 |
20160287703 | BPO WASH GEL COMPOSITION - A topical dermatological/pharmaceutical composition is described that includes BPO wherein the composition is a wash composition with desirable tolerance, stability and foaming properties. The composition can include: a) benzoyl peroxide (BPO); b) at least one mild surfactant selected from anionic and/or non-ionic surfactant classes; c) zinc gluconate; d) dipotassium glycyrrhizate; and e) at least one gelling agent. The composition is preferably in the form of an aqueous gel or an aqueous-alcoholic gel. Also described, is the use of such a composition for the treatment of dermatological disorders, and in particular in the treatment of acne. | 2016-10-06 |
20160287704 | Topical Pharmaceutical Cosmetic and Disinfectant Compositions Comprising Phosphatidylcholine - A topical carrier consists of 99% by weight or more of phosphatidylcholine and volatile solvent selected from the group consisting of: ethanol and its combinations with C3-and/or C4-alcohol and/or volatile silicone oil. The carrier may additionally comprise up to 1% by weight of antioxidant, colorant, odorant, and/or preservative, and up to 2% by weight of denaturant. Also disclosed are pharmaceutical, cosmetic and disinfectant compositions consisting of the carrier and pharmaceutically active agent, cosmetically active agent and/or disinfectant agent. | 2016-10-06 |
20160287705 | WOUND HEALING USING TOPICAL SYSTEMS AND METHODS - The present invention generally relates to compositions and methods for topical or transdermal delivery and treatment of wounds and/or promoting wound healing. In some cases, the composition may include nitric oxide and/or peptides such as thyrotropin-releasing hormone (TRH) and/or GnRH (gonadotropin-releasing hormone). The nitric oxide and/or peptide may be present within a first phase comprising a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present in liposomes, micelles, or other structures containing nitric oxide, peptides, or both. The composition can take the form of a gel, a cream, a lotion, an ointment, a solution, a solid “stick,” etc., that can be rubbed or sprayed onto the skin, e.g., wounded skin. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like. | 2016-10-06 |
20160287706 | DRUG CARRIER HAVING L-DNA NANOCAGE STRUCTURE - The present invention relates to a drug carrier having L-DNA nanocage structure prepared by using L-DNA, the mirror form of natural DNA, as a backbone. The drug carrier of the present invention has very superior cellular uptake efficiency and serum stability, so that it can be applied to deliver various drugs into cells usefully. | 2016-10-06 |
20160287707 | PHARMACEUTICAL COMPOSITION COMPRISING A POORLY WATER-SOLUBLE ACTIVE INGREDIENT, A SURFACTANT AND A WATER-SOLUBLE POLYMER - Solid composition comprising (a) an anionic surfactant in combination with a water-soluble and basic polymer, or (b) a cationic surfactant in combination with a water-soluble and acidic polymer, and (c) at least one poorly water-soluble pharmaceutically active ingredient, and solid or liquid dosage forms, especially tablets, coated tablets, capsules or suppositories or aqueous solutions comprising the solid composition. The surfactant/polymer system is soluble in water and solubilises the active ingredient so that good bioavailability with therapeutical quantities may be attained. Aqueous solutions are suitable for nasal, parenteral or ophthalmic treatments. | 2016-10-06 |
20160287708 | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device - A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is coated with a pharmaceutical composition consisting of a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis. | 2016-10-06 |
20160287709 | STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE - Methods of preparing lyophilized preparations of Factor IX which preserve more than 90% of the calcium binding property of Factor IX are disclosed. Factor IX formulated with trehalose shows a superior stability profile after 12 weeks storage at 25° C./60% relative humidity (RH) and 40° C./75% RH relative to Factor IX formulated without trehalose. The data suggest that the inclusion of trehalose in the formulation could allow for temperature excursions or even long-term room temperature storage of a Factor IX lyophilized product. The formulations tested contained 10 mM histidine pH 6.8, 3% mannitol, 66 mM sodium chloride, 0.0075% Polysorbate 80, with and without 1% trehalose. Upon storage at 40° C./75% RH or 25° C./60% RH over 12 weeks the trehalose-containing formulation was comparable to product stored at 2-8° C. while the formulation without trehalose was found to undergo significant aggregation and loss of activity. The two formulations demonstrated comparable stability over 26 weeks of real time storage at −20° C. and 2-8° C. | 2016-10-06 |
20160287710 | GLYCOL CHITIN BASED THERMOSENSITIVE HYDROGEL FOR VAGINAL DELIVERY OF PROGESTERONE - Compositions, methods, and kits for vaginal administration of progesterone are described. | 2016-10-06 |
20160287711 | Formulation Solution Adapted to Prolong Plasma Times of Drugs in Mammals Including Humans - Prolongation compositions for prolonging the presence of drugs in blood. | 2016-10-06 |
20160287712 | FATTY ACID NIACIN CONJUGATES - The invention provides fatty acid niacin conjugates; pharmaceutical compositions comprising an effective amount of the fatty acid niacin conjugate; and methods for treating or preventing a metabolic disease comprising the administration of an effective amount of the fatty acid niacin conjugate. | 2016-10-06 |
20160287713 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF - Methods and compositions are provided for extending the half-life of a therapeutic agent. One or more half-life extending moieties may be attached to a therapeutic agent, thereby extending the half life of the therapeutic agent. The modified therapeutic agents (mTAs) comprising one or more half-life extending moieties attached to a therapeutic agent may be used to treat a disease or condition in a subject in need thereof. | 2016-10-06 |
20160287714 | CARRIER FOR USE IN DELIVERING DRUG, CONJUGATE, COMPOSITION COMPRISING SAME, AND METHOD FOR ADMINISTRATING SAME - The present invention provides a vesicle, a conjugate, a composition comprising the vesicle or the conjugate, for use in delivering a drug to the brain, and a method for administering the same. The composition of the present invention is a composition for administration to a subject according to a dosing regimen, comprising a carrier for drug delivery, wherein the dosing regimen comprises administering the composition to a subject who has been fasted or caused to have hypoglycemia and inducing an increase in blood glucose level in the subject, and the carrier is modified at the outer surface thereof with a GLUT1 ligand. | 2016-10-06 |
20160287715 | MULTIFUNCTIONAL ZWITTERIONIC POLYMER CONJUGATES - The present invention provides random copolymers containing zwitterions and one or more functional agents, and methods of preparing such random copolymers. | 2016-10-06 |
20160287716 | METHOD FOR DELIVERY OF A BIOACTIVE SUBSTANCE NEAR/INTO A TARGET CELL - The present invention discloses a biocarrier for delivery of a bioactive substance near/into a target cell, comprising a bioactive substance-loaded core with a first electricity, and one or more block copolymer, each block copolymer comprising a zwitterionic block and an anchoring block with an initial electricity opposite to the first electricity, wherein the anchoring block binds to the core by electrostatic attraction, and the zwitterionic block extends outwardly to increase the biocarrier stability in mammalian blood. Additionally, the present invention also discloses a method of using the biocarrier. | 2016-10-06 |